Your browser doesn't support javascript.
loading
HRAS-driven cancer cells are vulnerable to TRPML1 inhibition.
Jung, Jewon; Cho, Kwang-Jin; Naji, Ali K; Clemons, Kristen N; Wong, Ching On; Villanueva, Mariana; Gregory, Steven; Karagas, Nicholas E; Tan, Lingxiao; Liang, Hong; Rousseau, Morgan A; Tomasevich, Kelly M; Sikora, Andrew G; Levental, Ilya; van der Hoeven, Dharini; Zhou, Yong; Hancock, John F; Venkatachalam, Kartik.
Afiliación
  • Jung J; Department of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
  • Cho KJ; Department of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State University, Dayton, OH, USA.
  • Naji AK; Department of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center, Houston, TX, USA.
  • Clemons KN; Department of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
  • Wong CO; Graduate Program in Biochemistry and Cell Biology, MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Villanueva M; Department of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
  • Gregory S; Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA.
  • Karagas NE; Patient Derived Xenografts and Advanced in vivo Models Core Facility, Baylor College of Medicine, Houston, TX, USA.
  • Tan L; Department of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
  • Liang H; Graduate Program in Biochemistry and Cell Biology, MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Rousseau MA; Department of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
  • Tomasevich KM; Graduate Program in Biochemistry and Cell Biology, MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Sikora AG; Department of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
  • Levental I; Graduate Program in Biochemistry and Cell Biology, MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
  • van der Hoeven D; Department of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
  • Zhou Y; Department of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
  • Hancock JF; Department of Integrative Biology and Pharmacology, McGovern Medical School, the University of Texas Health Sciences Center (UTHealth), Houston, TX, USA.
  • Venkatachalam K; Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA.
EMBO Rep ; 20(4)2019 04.
Article en En | MEDLINE | ID: mdl-30787043

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas p21(ras) / Canales de Potencial de Receptor Transitorio Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: EMBO Rep Asunto de la revista: BIOLOGIA MOLECULAR Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas p21(ras) / Canales de Potencial de Receptor Transitorio Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: EMBO Rep Asunto de la revista: BIOLOGIA MOLECULAR Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos